ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Chronic myelomonocytic leukemia complicated with T-lymphoblastic lymphoma: a case report and literature review].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coexistence of chronic myelomonocytic leukemia (CMML) and T-lymphoblastic lymphoma (T-LBL) is extremely rare. We report a 65-year-old female patient who presented with occipitocervical masses, fever, and night sweats for 1 month. Comprehensive examinations, including bone marrow aspiration, lymph node biopsy, flow cytometry, and molecular profiling, confirmed the diagnosis of CMML-1 combined with T-LBL. The patient achieved complete remission of T-LBL after VDCP chemotherapy (vindesine, daunorubicin, cyclophosphamide, and dexamethasone), but later relapsed and progressed to T-lymphoblastic leukemia (T-ALL). After unsuccessful salvage therapies, she was treated with venetoclax combined with the CHG regimen, which induced a second complete remission of T-ALL. Notably, the CMML remained indolent throughout the clinical course. This article, supplemented with a literature review, emphasizes the clinicopathological features, molecular mechanisms, and therapeutic strategies for this rare coexistence, thereby highlighting the importance of multidisciplinary collaboration and individualized management in rare hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.